IP Library Patent Application 19007152
Patent Application
App. No. 19/007,152

ARTIFICIAL EXPRESSION CONSTRUCTS FOR SELECTIVELY MODULATING GENE EXPRESSION IN INTERNEURONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/007,152
Abstract

Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in GABAergic interneurons.

Claims (32)

1 .- 51 . (canceled)

52 . A method for expressing a coding sequence within a targeted population of cells in vivo, the method comprising administering to a living subject an administrable composition comprising an artificial expression construct comprising:

i) a concatemer comprising 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of a sequence consisting of SEQ ID NO: 2 or SEQ ID NO: 6;

ii) a promoter; and

iii) a coding sequence,

in a sufficient dosage and for a sufficient time to the living subject comprising the population of cells thereby expressing the coding sequence within the population of cells.

53 . The method of claim 52 , wherein the coding sequence encodes a fluorescent protein or an ion transporter selected from a potassium channel or a calcium channel.

54 . The method of claim 52 , wherein the coding sequence encodes an enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channel rhodopsin, CRISPR/CAS molecule, editase, guide RNA molecule, homologous recombination donor cassette, or DREADD.

55 . The method of claim 52 , wherein the living subject is a human, non-human primate, or a mouse.

56 . The method of claim 52 , wherein the administering is through injection.

57 . The method of claim 56 , wherein the injection comprises intravenous injection, intraparenchymal injection into brain tissue, intracerebroventricular (ICV) injection, intra-cisterna magna (ICM) injection, or intrathecal injection.

58 . A method for expressing a coding sequence within a targeted population of cells in vitro, the method comprising providing an administrable composition comprising an artificial expression construct comprising:

i) a concatemer comprising 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of a sequence consisting of SEQ ID NO: 2 or SEQ ID NO: 6;

ii) a promoter; and

iv) a coding sequence,

in a sufficient dosage and for a sufficient time to a sample comprising the population of cells thereby expressing the coding sequence within the population of cells.

59 . The method of claim 58 , wherein the coding sequence encodes a fluorescent protein or an ion transporter selected from a potassium channel or a calcium channel.

60 . The method of claim 58 , wherein the coding sequence encodes an enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channel rhodopsin, CRISPR/CAS molecule, editase, guide RNA molecule, homologous recombination donor cassette, or DREADD.

61 . The method of claim 58 , wherein the providing comprises pipetting to a brain slice.

62 . The method of claim 61 , wherein the brain slice includes a GABAergic interneuron.

63 . The method of claim 61 , wherein the brain slice includes a lysosomal associated membrane protein 5 (LAMP5) neuron, a vasoactive intestinal peptide (Vip) neuron, a somatostatin (Sst) neuron, or a parvalbumin (Pvalb) neuron.

64 . A transgenic cell comprising an artificial expression construct comprising:

i) a concatemer comprising 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of a sequence consisting of SEQ ID NO: 2 or SEQ ID NO: 6;

ii) a promoter; and

iii) a coding sequence.

65 . The transgenic cell of claim 64 , wherein the transgenic cell is a GABAergic interneuron.

66 . The transgenic cell of claim 64 , wherein the transgenic cell is a lysosomal associated membrane protein 5 (LAMP5) neuron, a vasoactive intestinal peptide (Vip) neuron, a somatostatin (Sst) neuron, or a parvalbumin (Pvalb) neuron.

67 . The transgenic cell of claim 64 , wherein the transgenic cell is murine, human, or non-human primate.

68 . The transgenic cell of claim 64 , wherein the coding sequence encodes a fluorescent protein or an ion transporter selected from a potassium channel or a calcium channel.

69 . The transgenic cell of claim 64 , wherein the concatemer has 3 copies of the sequence consisting of SEQ ID NO: 2 or 3 copies of the sequence consisting of SEQ ID NO: 6.

70 . The transgenic cell of claim 64 , wherein the artificial expression construct is associated with a capsid that crosses a blood brain barrier.

71 . The transgenic cell of claim 64 , wherein the artificial expression construct is within a viral vector.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2025
From: TING, JONATHAN; LEVI, BOAZ P.; MICH, JOHN K.; LEIN, EDWARD SEBASTIAN
To: ALLEN INSTITUTE
Reel/Frame 071078/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2025
From: KALUME, FRANCK
To: SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE)
Reel/Frame 071078/0664 →